The Top 5 Biosimilars Articles for the Week of November 25

The Center for Biosimilars® recaps the top stories for the week of November 25, 2019.


Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of November 25, 2019.

Number 5: Could there be trouble ahead for Alexion? A Roche subsidiary has claimed that the drug maker infringed on its patent for a technology that extends the half-lives of antibodies.

Number 4: Studies of single-agent immune checkpoint inhibitors in ovarian cancer have shown limited activity, but combination therapy with bevacizumab may hold promise.

Number 3: Researchers report that an unfolding microneedle injector could be a feasible delivery device for biologic drugs like insulin.

Number 2: A new study from the Nordic region shows similar retention rates for patients who start treatment with reference or biosimilar infliximab or etanercept.

Number 1: Data presented during the European Society for Medical Oncology Asia Congress 2019, held last week in Singapore, support the biosimilarity of HLX02 and Herceptin.

Finally, last week, our e-newsletter asked whether you think that we will continue to see more relatively deep discounts on biosimilars’ list prices after Ziextenzo launched at a 37% discount.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit

Related Videos
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Nabil Saba
Ryan Haumschild, PharmD
Julie M. Reed
Gillian Woollett, MA, Dphil
Julie M. Reed
Related Content
© 2023 MJH Life Sciences

All rights reserved.